Aardvark Therapeutics catat rugi bersih Q2 FY26 USD 14,4 juta; kas per 30 Juni FY26 turun 18,97% jadi USD 73,9 juta

Reuters2026/08/11 20:53

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Aardvark Therapeutics membukukan rugi bersih GAAP kuartal II sebesar 14,39 juta, relatif datar dari periode yang sama tahun lalu.
Rugi per saham GAAP bertahan di 0,66; belanja R&D turun 20,46% menjadi 10,46 juta.
Beban G&A melonjak 71,25% menjadi 4,63 juta; kas, setara kas, dan investasi jangka pendek susut menjadi 73,9 juta per 30 Juni.
Perusahaan menghentikan uji Phase 3 HERO dan OLE untuk ARD-101 pada Juni, menilai data tak-terbuta pada kuartal III.
Tien Lee mengatakan Aardvark tetap berdiskusi aktif dengan FDA untuk menyelesaikan clinical hold; kas diproyeksikan mendanai operasi hingga akhir 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608111653PRIMZONEFULLFEED9808151) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Aardvark Therapeutics catat rugi bersih Q2 FY26 USD 14,4 juta; kas per 30 Juni FY26 turun 18,97% jadi USD 73,9 juta

You may also like

Crypto prices